Discover how LCC’s highly developable chemical space has been designed to support projects from hit identification, to hit expansion and lead optimisation.
Designed to deliver quality and rapid science to our clients, LCC’s chirally-pure, sp3-rich scaffolds are co-located with our expert chemistry team and parallel synthesis laboratory.
LCC supports orthogonal Hit Identification approaches and technologies:
Founded in 2014, LCC is now established as one of the top chemical technology innovators in the industry.
We believe that curiosity driven by purpose leads to new ideas and faster progress. By offering improved access to 3D chemical space, we help to accelerate the discovery and development of high-quality drugs.
Innovative thinking at LCC drives new ideas, and the collaborative work of the team executes them. Read more here about the latest products at LCC:
We have designed and enumerated a 1.4Bn member Ultra-Large Virtual Library that can be screened in 3D. It is stereodefined, diverse, novel, 3D-rich and synthetically tractable.
The library has been designed by reaction-based enumeration of LCC’s proprietary (chiral) scaffolds, which are co-located with our parallel synthesis laboratory for rapid synthesis of hits.
Screen LCC's ULVL in 3D using OpenEye's Orion® platform, which provides accurate conformational sampling and retains the chirality.
We have designed and enumerated a covalent virtual library based on LCC's chirally-pure, multi-functional scaffolds.
The covalent VL includes >800k compounds functionalised with the same warhead (acrylamide) and it has been enumerated based on the scheme shown (left):
LCC is excited to announce our new Kinase-Focused VL featuring pre-defined near-neighbour analogues:
LCC and OpenEye, Cadence Molecular Sciences are proud to announce the launch of a drug-like virtual library of >1 billion compounds that will be available in OpenEye’s cloud-native Orion® molecular design platform.More Information